
Canadian precious metals producer SSR Mining announced it would to buy Alacer Gold in an all-stock deal valued at CA$2.41 billion (US$1.72 billion), adding heft as gold prices surge due to demand for the yellow metal in an uncertain economy, reported Reuters.
Gold miners have benefited from a 12% jump in prices this year as investors seek safer assets to shield themselves from the damaging impact of the coronavirus outbreak on the global economy.
The move also comes on the back of a record year of mergers and acquisitions in the sector, including some of the biggest deals in a decade in 2019.
The new company, which will be headquartered in Denver, Colorado, will have operational mines in four countries and will be led by Alacer CEO Rodney Antal, the two companies said on Monday, May 11.
“The combination … vaults us into the upper echelon in the peer group in terms of free cash flow generation,” Antal said in a conference call with analysts.
Alacer has focused over the past several years on free cash flow generation, and this merger allows the miner to continue this strategy while diversifying its single operating asset exposure, Antal said.
SSR Mining has operations in Nevada, United States, Saskatchewan, Canada, and Jujuy, Argentina, while Alacer is a low-cost gold producer focused on its cornerstone Çöpler Gold Mine in Turkey.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas